Prognostic Value of Central and BracHial Ambulatory Blood Pressure Monitoring in ERSD Patients Treated With HeMOdialysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-10

Study Completion Date

2020-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective cohort study which aims to explore the significance of brachial and central ambulatory blood pressure monitoring in predicting cardiovascular risk in patients with end stage renal disease who are treated with hemodialysis. Enrolled patients will receive a 48-hour central and brachial ambulatory blood pressure monitoring at its first-time dialysis after enrollment. And their cardiovascular events and deaths at first and third year will be followed-up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Pressure Measurement in Dialysed Patients

NCT03318653

End Stage Renal Disease

COMPLETED

Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension

NCT07033260

Intradialytic Hypotension End-Stage Renal Disease Requiring Haemodialysis Uremia; Chronic +1 more

RECRUITING

Hemodialysis-Induced Blood Pressure Change In End-Stage Renal Disease

NCT04933006

Hemodialysis

COMPLETED

Effects of Increasing Mean Arterial Pressure on Renal Function in Patients with Shock and with Elevated Central Venous Pressure

NCT05655065

Shock

RECRUITING NA

Whole Exome Sequencing in CKD Hypertension

NCT03718585

Hypertension;Nephropathy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The protocol of this study was approved by the local ethical review board. The including criteria: 1) ESRD treated with hemodialysis for more than 3 months prior to study enrollment; 2) agree to participate the study and sign informed written consent; 3) available for long-term follow-up. The excluding criteria: 1)chronic atrial fibrillation or other cardiac arrhythmia; 2) nonfunctional arteriovenous fistula in the contralateral brachial area of the one used for dialysis; 3) myocardial infarction, angina pectoris and ischemic stroke during the previous month; 4) congestive heart failure class IV based on the New York Heart Association classification; 5) malignancy or any other condition with poor prognosis; 6) antihypertensive treatment during one month prior to enrollment. After enrollment, every patient will receive a question-based interview to obtain medical history and the following examinations and tests: anthropometric parameters measurement including body height, weight; biochemical tests including vein blood and urine. At the first-time dialysis after enrollment, patients will receive 48-hour central and brachial ambulatory blood pressure monitoring using a well validated and commercial device Mobil-O-Graph (IEM, Germany). Brachial blood pressure are measured for each patient before every dialysis for at three month. Then one-year and three-year cardiovascular events and deaths will be followed-up. The primary outcome measures are as follows: deaths and cardiovascular events including nonfatal myocardial infarction, unstable angina, stroke, hospitalization for heart failure, or resuscitated cardiac arrest.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

48-hour blood pressure ambulatory monitoring

at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with end-stage renal disease treated with hemodialysis for more than 3 months prior to study enrollment;
* agree to participate the study and sign informed written consent;
* available for long-term follow-up.

Exclusion Criteria

* chronic atrial fibrillation or other cardiac arrhythmia;
* nonfunctional arteriovenous fistula in the contralateral brachial area of the one used for dialysis;
* myocardial infarction, angina pectoris and ischemic stroke during the previous month;
* congestive heart failure class IV based on the New York Heart Association classification;
* malignancy or any other condition with poor prognosis;
* antihypertensive treatment during 1 month prior to enrollment.

Eligible Sex

ALL

Accepts Healthy Volunteers

No